(MT Newswires) -- Bristol-Myers (BMY) CEO Christopher Boerner discusses the company's transition, marked by a series of transactions and the development of new drugs, particularly in neuroscience and oncology. He talks about growth prospects, the pipeline of 16 new drugs in development between now and the end of the decade, and the return of capital to shareholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.12 USD | +2.17% | -0.28% | -19.85% |
May. 30 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
May. 30 | Bristol Myers: FDA approval for Breyanzi | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.85% | 83.29B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology